[Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers  by Barnetson, Ross StC et al.
[Nle4-D-Phe7]-a-Melanocyte-Stimulating Hormone
Significantly Increased Pigmentation and Decreased
UV Damage in Fair-Skinned Caucasian Volunteers
Ross StC. Barnetson1, Terry K.T. Ooi1, Liqing Zhuang1, Gary M. Halliday1, Catherine M. Reid2,
Patrick C. Walker2, Stuart M. Humphrey3 and Michael J. Kleinig3
Epidermal melanin reduces some effects of UV radiation, the major cause of skin cancer. To examine whether
induced melanin can provide protection from sunburn injury, 65 subjects completed a trial with the potent
synthetic melanotropin, [Nle4-D-Phe7]-a-melanocyte-stimulating hormone ([Nle4-D-Phe7]-a-MSH) delivered by
subcutaneous injection into the abdomen at 0.16 mg/kg for three 10-day cycles over 3 months. Melanin density,
measured by reflectance spectroscopy, increased significantly in all [Nle4-D-Phe7]-a-MSH-treated subjects. The
highest increases were in volunteers with lowest baseline skin melanin levels. In subjects with low minimal
erythemal dose (MED) skin type, melanin increased by an average of 41% (from 2.55 to 3.59, Po0.0001 vs
placebo) over eight separate skin sites compared with only 12% (from 4.18 to 4.70, Po0.0001 vs placebo) in
subjects with a high-MED skin type. Epidermal sunburn cells resulting from exposure to 3 MED of UV radiation
were reduced by more than 50% after [Nle4-D-Phe7]-a-MSH treatment in the volunteers with low baseline MED.
Thymine dimer formation was also shown to be reduced by 59% (P¼ 0.002) in the epidermal basal layer. This
study has shown for the first time the potential ability of a synthetic hormone that augments melanin
production to provide photoprotection to people who normally burn in direct sunlight.
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INTRODUCTION
Melanin is synthesized in a multistep biochemical pathway
within melanocytes situated in the epidermis, the most
superficial layer of the skin (Chaturvedi and Hadley, 1988;
Hadley et al., 1993). UVR, especially UVB, causes the
release of a- melanocyte-stimulating hormone (a-MSH) from
cutaneous keratinocytes and melanocytes. Unfortunately, in
this process, significant UVR-induced skin damage needs to
occur in order to trigger this release (Gilchrest et al., 1996).
a-MSH binds to melanocortin-1-receptor on the melanocytes
to induce synthesis of melanin and produce tanned skin
(Chaturvedi and Hadley, 1988; Hadley et al., 1993). The
increased melanin subsequent to UVR may provide protec-
tion from the further damaging effects of solar radiation
(Pathak, 1995).
Several studies have suggested that individuals whose skin
tends to burn easily on exposure to the sun and does not tan
readily are at a higher risk of both non-melanoma skin tumors
and of cutaneous melanoma (Stenback, 1978; Fitzpatrick,
1988; Kricker et al., 1995b). Such poorly tanning individuals,
termed types I and II in the Fitzpatrick scale (Fitzpatrick,
1988), typically possess defects in the melanocortin-1-
receptor gene (Valverde et al., 1995) and are generally
thought to be at a greater risk of developing skin cancer
(Epstein, 1983; Sober et al., 1991; Palmer et al., 2000; Box
et al., 2001).
Stimulating melanin production without the associated
cell damage caused by UVR may prove an extremely
important addition to the photoprotective strategies being
advocated to try and reduce the increasing incidence of skin
cancer in the world, especially in most fair-skinned popula-
tions (Armstrong and Kricker, 1994). Several derivatives of
a-MSH have been synthesized (Sawyer et al., 1980; Castrucci
et al., 1984; Hruby et al., 1993). One of these molecules,
[Nle4-D-Phe7]-a-MSH, was used in this study. [Nle4-D-Phe7]-
a-MSH is more potent and long lasting than a-MSH (Sawyer
et al., 1980). Several studies on human volunteers have been
performed and have clearly demonstrated that [Nle4-D-Phe7]-
a-MSH can induce safe and effective tanning in humans at an
optimum dose of 0.16 mg/kg/day for 10 days (Levine et al.,
1991, 1999; Dorr et al., 2000). However, these studies have
been generally limited to small cohorts of volunteers who are
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known to tan easily in response to sunlight (Fitzpatrick scale
III–IV) and to a dosage regimen of only 10 days. Previous
results have shown increased pigmentation predominantly in
the sun-exposed areas of skin such as the forehead, cheek,
and shoulder.
In the current placebo-controlled study, we aimed to
establish (1) the safety and tolerability in Caucasian subjects
of a prolonged dosage treatment (three monthly courses of
[Nle4-D-Phe7]-a-MSH at a fixed subcutaneous dose of
0.16 mg/kg/day for 10 days in each course), (2) determine
whether 30 days of dosing increased the tanning effect
compared to 10 days, (3) study the degree of tanning at
different anatomical sites and in subgroups of Caucasians
with UV-sensitive (low-threshold minimal erythema dose
(MED)) compared with relatively UV-insensitive (high-thresh-
old MED) skin, and (4) determine whether facultative tanning
could protect against UVR-induced skin damage.
RESULTS
A total of 79 subjects were enrolled in the study, 59
randomized to [Nle4-D-Phe7]-a-MSH and 20 to placebo. All
subjects were Caucasian (46 male and 33 female subjects)
with a mean7SD age in the [Nle4-D-Phe7]-a-MSH group of
37.6715.5 years and in the placebo group of 44.5717.6
years. In the [Nle4-D-Phe7]-a-MSH group, 47/59 (80%)
completed the study, whereas 18/20 (90%) subjects receiving
placebo completed the study. Injections of [Nle4-D-Phe7]-a-
MSH were associated with four major side effects that have
been previously observed, namely nausea (experienced by
85% of subjects), facial flushing (74%), fatigue (44%), and
vomiting (26%). Injection site reactions occurred in 13% of
the subjects. There were no significant changes in vital signs,
hematological parameters, or blood biochemistry (including
liver and renal function tests). Fourteen subjects withdrew
during the 3-month duration of the study (12 active and two
placebo) with the most common reason in the [Nle4-D-Phe7]-
a-MSH group (n¼9) being problems with nausea, three
others were either lost to follow-up (1), or withdrew owing to
side effects associated with bruising at the site of injections
(2). Therefore, 65 subjects completed the full protocol
including skin biopsy assessment. The most common skin
type found was the low-MED subgroup (easily burn) assigned
to 44 (68%) subjects (30 [Nle4-D-Phe7]-a-MSH and 14
placebo). The average MED in this subgroup was
311711 mJ/cm2 (range 167–426). Twenty-one subjects
(32%) were assigned to the high-MED subgroup (rarely burn)
(17 [Nle4-D-Phe7]-a-MSH and four placebo). The average
MED in this subgroup was 611722 mJ/cm2 (range 457–840).
Pigmentation change
The change from baseline to day 90 for melanin density (MD)
and luminance (L*) was compared between the two treatment
groups, [Nle4-D-Phe7]-a-MSH and placebo, using an analysis
of variance model with skin type and treatment group as
factors and an interaction factor (skin type treatment
group). At all skin sites, MD increased in [Nle4-D-Phe7]-a-
MSH-treated subjects and decreased in placebo controls. An
increase in darkening, signified by a decrease in L*, was also
seen in [Nle4-D-Phe7]-a-MSH-treated subjects, whereas skin
color lightened in placebo controls. Importantly, the P-value
for the difference between treatment groups was highly
significant at all times, for all sites and overall (Po0.0001).
The effect of [Nle4-D-Phe7]-a-MSH on skin sites designated as
sun-exposed (namely, forehead, cheek, neck, and forearm)
compared with non-sun-exposed (namely, shoulder, inner
upper arm, abdomen, and calf) in the two groups ([Nle4-D-
Phe7]-a-MSH vs placebo) is shown graphically (expressed as
a percentage MD change (upper) and L* value change (lower)
from baseline) in Figure 1. There was no significant difference
between sun-exposed and non-sun-exposed skin sites. For
MD, the site where the largest differences occurred between
treatment groups in the change from baseline to day 90 was
in the abdomen, forehead, and inner upper arm. The adjusted
(least squares) mean7SEM change in MD from baseline to
day 90 for the abdomen was 1.0670.13 in the [Nle4-D-Phe7]-
a-MSH group and 0.1570.08 in the placebo, and mean
(95% confidence interval) for difference between treatment
groups was 1.17 (0.78, 1.56), Po0.0001. For the forehead,
the values were 1.0070.10 and 0.1070.09 ([Nle4-D-Phe7]-
a-MSH and placebo), a difference of 1.09 (0.76, 1.42),
Po0.0001. For the inner upper arm, there was a change of
0.8570.09 with [Nle4-D-Phe7]-a-MSH compared to a de-
crease of 0.370.11 in placebo, a difference of 1.00 (0.81,
1.44), Po0.0001.
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Figure 1. Mean change in MD and luminance (L*) for sun-exposed and
non-sun-exposed skin sites in [Nle4-D-Phe7]-a-MSH-treated and placebo
subjects. MD and skin darkening (L*) were determined at eight skin sites by
skin reflectance using a Minolta spectrophotometer at different times (days)
throughout the study. Four skin sites (forehead, cheek, neck, and forearm)
were combined as sun-exposed skin sites and four (shoulder, inner upper
arm, abdomen, and calf) combined as unexposed skin sites. The mean of 47
[Nle4-D-Phe7]-a-MSH (’) and 18 placebo (J) is shown as the change from
baseline measurement at day 0. Sun-exposed skin sites are shown by the solid
lines and unexposed skin sites by the dashed line. The same sites have the
same symbols in the two (a and b). Symbols represent the mean for each
group and the bars represent SEM. (a) MD increases in [Nle4-D-Phe7]-a-MSH-
but not in placebo-treated subjects in both sun-exposed and unexposed skin
sites. Unexposed sites showed a smaller increase, but the difference was not
statistically significant. Differences between treated and placebo were highly
significant at all sites (Po0.0001). (b) Decrease on the L* scale (indicating
skin darkening) occurred in the [Nle4-D-Phe7]-a-MSH-treated group at all skin
sites and an increase occurred in placebo-treated subjects. The difference
between [Nle4-D-Phe7]-a-MSH-treated and placebo was highly significant
(Po0.001), whereas differences between exposed and unexposed skin sites in
either group were not significant.
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The average L* (inclusion of all eight skin sites) decreased
by 1.16þ0.25 (from 61.8þ1.15 to 60.64þ1.17) in the
treated group over the 90 days, whereas the placebo group
increased by 1.34 (60.51þ0.77 to 61.85þ0.70), giving an
overall significant difference between active and placebo of
2.50 (P¼ 0.0283). The largest changes were in the neck and
abdomen (1.95þ 0.53 and 1.89þ0.53, respectively).
A comparison of the effects of [Nle4-D-Phe7]-a-MSH on
subjects categorized as low and high MED is shown in
Figure 2. For simplicity, only the MD values are illustrated
although similar but less demonstrable changes were seen
with the L* criteria. Overall, the change in MD in the low-
MED skin type population (active; n¼ 30) was approximately
double that of the high-MED skin type (active; n¼17)
(1.0470.13 vs 0.5270.09, respectively; Po0.0001). This
represents an average increase over all skin sites in the low-
MED group of about 41% (1.04/2.55) and only 12% (0.52/
4.18) in the high-MED group. Conversely, the placebo groups
showed a decrease of 6 and 12% in MD (high- and low-MED
groups, respectively). In contrast to the low-MED group, the
overall treatment effect in the high-MED group was com-
prised of approximately equal but opposite small changes in
the active and placebo subjects. An example of the
pigmentation change in the face of a subject from the low-
MED group is shown in Figure 3.
To assess the change in pigmentation in the treatment
group overall, a plot was generated of the maximum change
in MD at the inner upper arm compared with the equivalent
baseline MD. The inner upper arm was chosen to represent
the most likely value for the constitutive melanin. This is
shown in Figure 4 and demonstrates that the lower the
starting MD, the greater the effect of [Nle4-D-Phe7]-a-MSH.
So the persons with a baseline MD of 3 or less generally
showed increases of 1 or more, whereas those with 4 or more
at starting level exhibited only a small (average 0.3 unit)
increase. The results indicate that [Nle4-D-Phe7]-a-MSH
treatment was associated with an approximate doubling in
MD for individuals with the lowest baseline MD (Figure 4).
Biopsy of melanin-containing cells
Sections from skin biopsy samples taken at day 0 (baseline)
and day 90 were stained for melanin. Figure 5 shows the
relative levels for low- and high-MED skin types at these
times. At the start of treatment, melanin levels were higher in
the high-MED group than in the low-MED group (as
expected). In both placebo groups, the melanin skin content
fell slightly from baseline to day 90 (8297191 to 7267150
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Figure 2. Comparative change in overall MD in low- and high-MED skin
types with and without [Nle4-D-Phe7]-a-MSH. The increase in MD in
volunteers treated with [Nle4-D-Phe7]-a-MSH was greater in subjects with a
low MED than in subjects with a high MED. MD was determined by skin
reflectance using a Minolta spectrophotometer at different times (days)
throughout the study. The subjects were divided into two groups with low
and high MED: [Nle4-D-Phe7]-a-MSH-treated low-MED subjects (n¼30,
circles, full line), placebo-treated low-MED subjects (n¼ 14, J, - - - - -),
[Nle4-D-Phe7]-a-MSH-treated high-MED subjects (n¼ 17, W, —) and
placebo-treated high-MED subjects (n¼4, W, - - - - - -).
a b
Figure 3. Skin pigmentation with [Nle4-D-Phe7]-a-MSH. Subject no. 39 in the
low-MED group (a) before and (b) 60 days after the start of [Nle4-D-Phe7]-a-
MSH treatment. The MD of the forehead increased from 1.68 to 2.89, and
left cheek from 2.99 to 3.64.
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Figure 4. MD change in the inner upper arm after 90 days, [Nle4-D-Phe7]-a-
MSH versus baseline values. The increase in MD in volunteers treated with
[Nle4-D-Phe7]-a-MSH was greater in subjects with low levels of constitutive
melanin. MD at the inner upper arm (non-sun-exposed site) was determined
by skin reflectance using a Minolta spectrophotometer for 47 subjects who
completed the course of treatment with [Nle4-D-Phe7]-a-MSH. Baseline
measurements at day 0 are plotted against the increase in MD on day 90 at the
end of the study (MD at day 90MD at day 0). Each subject is shown as an
individual point. The line of best fit generated by linear regression analysis is
shown as a solid line. Statistical analysis is by linear regression.
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and 2,2707166 to 2,2607112 melanin-positive cells per
mm2, for low- and high-MED groups, respectively), in
agreement with the spectrophotometric data. Skin melanin
content increased significantly in the low-MED subjects by
approximately 61% from 901þ103 to 1,453þ137 melanin-
positive cells per mm2 (Po0.001). In contrast, melanin levels
remained unchanged in the high-MED subjects (1,917þ148
to 1,917þ134 melanin-positive cells per mm2). The data are
illustrated in Figure 6 in which photomicrographs of biopsies
taken at baseline (Figure 6a) and day 90 (Figure 6b) for a
subject in the low-MED group are shown. Abundant melanin
stain can be seen as supranuclear capping of cells after
treatment with only minimal melanin staining observed at
baseline.
Sunburn injury estimation
For those subjects who showed a large increase in melanin,
namely the low-MED group of subjects, the possible
protective effect of this increased melanin was assessed by
measuring the number of sunburn (apoptotic) cells/mm length
of epidermis resulting from exposure to 3 individual’s MED
at the beginning and end of the study period (day 90). This
was determined by light microscopy and the results are
shown in Figure 7a. There was a highly statistical (Po0.001)
(paired t-test) reduction in the number of sunburn cells in the
treated population with no significant change in the placebo
group (P¼ 0.806). This represents a reduction by more than
50% in sunburn cell injury at the end of the study after [Nle4-
D-Phe7]-a-MSH treatment compared with 26% in the
equivalent placebo group. The variable response in the
placebo individuals resulted in the difference between [Nle4-
D-Phe7]-a-MSH and placebo being nonsignificant (P¼0.28)
(unpaired t-test). A slide showing sunburn cells is shown in
Figure 7b following 3MED, and before treatment with
[Nle4-D-Phe7]-a-MSH.
Thymine dimer (T–T) assessment
The number of nuclei stained for the presence of thymine
dimers in the epidermis of eight low baseline MED subjects
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Figure 5. Epidermal melanin content in treated and untreated subjects.
Epidermal melanin detected by Masson-Fontana staining and image analysis
was increased by [Nle4-D-Phe7]-a-MSH treatment in subjects with low MED.
Sections from biopsies were stained by Masson-Fontana for melanin. MD was
determined by image analysis (arbitrary units). The meanþ SEM is shown for
groups of subjects with low and high MED who were treated with placebo
(&) or [Nle4-D-Phe7]-a-MSH (’). Statistical comparisons between samples
taken at baseline on day 0 and at day 90 upon completion of the study in the
same subjects are shown in the figure (paired t-test). Low-MED placebo,
n¼ 14; low-MED [Nle4-D-Phe7]-a-MSH, n¼30; high-MED placebo, n¼4;
high-MED [Nle4-D-Phe7]-a-MSH, n¼ 16*. *Biopsy specimen from one subject
in the high-MED [Nle4-D-Phe7]-a-MSH group was lost.
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Figure 6. Photomicrographs of sections of epidermis labelled to visualize
melanin. Representative photomicrographs of one subject with a low MED
who had been exposed to 3 the subject’s MED on (a) day 0 and (b) again on
day 90 upon completion of the study. Paraffin-embedded section stained with
Masson-Fontana stain for melanin (brown pigment counterstained with
Sasranin). Melanin, indicated by arrows, can be seen as supranuclear capping
in many cells in (b) but only sparsely in the basal layer of (a). Bar¼ 0.10 mm.
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Figure 7. (a) Effect of [Nle4-D-Phe7]-a-MSH on sunburn cell response to 3
MED of solar-simulated UVR in the low-MED group. [Nle4-D-Phe7]-a-MSH
decreases the number of 3 MED-induced sunburn cells in subjects with low
MED. Subjects with a low MED were treated with placebo (n¼14) or [Nle4-D-
Phe7]-a-MSH (n¼ 30). Areas on the lower back/buttock were exposed to 3
the MED of that individual on day 0 and again on day 90 upon completion of
the study. Sections from biopsies were stained with hematoxylin and eosin
and sunburn cells identified by light microscopy were counted per mm length
of epidermis. Sunburn cells were not detected in matched unirradiated
samples from each subject. The meanþ SEM is shown for each group.
Statistical comparisons between samples taken at baseline on day 0 and at
day 90 upon completion of the study in the same subjects showed no
significant difference (paired t-test). (b) Sunburn cells in the epidermis.
Sunburn cells, as indicated by the arrows, shown in a trial subject following
3MED and before treatment with [Nle4-D-Phe7]-a-MSH. Bar¼ 0.10 mm.
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24 hours after exposure to 3MED before and after [Nle4-D-
Phe7]-a-MSH treatment is shown in Figure 8. T–T dimers were
reduced from a mean of 344þ25 to 161þ34 or by 53%
(P¼0.0036, paired t-test; Figure 8) after 90 days of [Nle4-D-
Phe7]-a-MSH compared to baseline levels in the whole
epidermis. The dimer levels were also measured specifically
in the basal layer and an even greater reduction was observed
in this region (97þ10 to 40þ 12 or by 59%; P¼ 0.002). A
representative photomicrograph of the epidermis before and
after 3MED in one subject is shown in Figure 9 indicating
the reduction in the brown-stained nuclei after treatment.
DISCUSSION
In this study, we have shown a highly significant increase in
melanin in [Nle4-D-Phe7]-a-MSH-treated individuals com-
pared to placebo, particularly in the fairer skin types, that is,
those with a low MED threshold. In this group, an average
increase of about 40% in skin melanin levels compared to
baseline was shown. This was associated with a reduction in
solar-simulated UVR skin damage of approximately 50%.
The two major forms of pigment present in human skin are
the dark brown/black eumelanin and the yellow/red, sulfur-
containing pigment, pheomelanin (Prota, 1980). The lowest
concentration of eumelanin and the highest phaeomelanin/
eumelanin ratio are found in the epidermis of Caucasians
with lightly pigmented skin and red or blond hair (Fitzpatrick
skin types I and II) when compared to individuals with darkly
pigmented skin and black hair (Fitzpatrick skin types III and
IV) (Thody et al., 1991; Hunt et al., 1995a; Dwyer et al.,
2000).
Individuals with a predominance of phaeomelanin in their
skin and/or a reduced ability to produce eumelanin may
explain why they fail to tan and are at risk from UVR.
Importantly, it has been shown in recent years that it is
eumelanin that is preferentially produced when a-MSH or
[Nle4-D-Phe7]-a-MSH initiates melanogenesis in human
melanocytes (Hunt et al., 1995b; Furumura et al., 1996;
Abdel-Malek et al., 1999, 2000; Thody, 1999; Dorr et al.,
2000). Indeed, Dorr et al. (2000) showed that administration
of 10 daily injections over 2 consecutive weeks of [Nle4-D-
Phe7]-a-MSH at a similar dose to that used in the current
study induced a preferential increase in eumelanin:pheo-
melanin ratio of subjects with type III/IV skin. The mechan-
isms proposed for photoprotection by eumelanin include but
are not limited to the absorption and scattering of UV light,
free radical scavenging, and quenching of UV light (Pathak,
1995). The photoprotection of epidermal melanin pigmenta-
tion is essentially independent of UV wavelength (Kollias
et al., 1996). Therefore, although the eumelanin/phaeomela-
nin ratio was not determined in this study, it can be
reasonably assumed that the increased melanin observed
was eumelanin.
Overwhelming epidemiological data demonstrate that
melanin in the skin confers protection from sunlight-induced
skin cancer, and the greater the level of melanin, the greater
the level of protection (Armstrong and Kricker, 1993; Kricker
et al., 1995a; Dwyer et al., 2002). It is interesting to note that
those with negroid skin (Fitzpatrick skin type VI) have a built-
in sun protection factor of 13.4 (Kaidbey et al., 1979). There
is no doubt that melanin in human skin attenuates the
penetration of UV light (Chedekel, 1995), the higher the
concentration of melanin, the more attenuation: melanin acts
as a neutral density filter throughout the UV spectrum (Kollias
et al., 1991). The important question is whether this
attenuation results in human photoprotection. Dwyer et al.
(2002) recently concluded from measurements of cutaneous
MD at the upper inner arm of Caucasian men living in
Australia that those with 0–1% melanin were associated with
approximately seven times greater relative risk of malignant
melanoma or basal cell carcinoma than men with X3%
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Figure 8. Effect of [Nle4-D-Phe7]-a-MSH on thymine dimer count in response
to 3 MED of solar-simulated UVR. [Nle4-D-Phe7]-a-MSH decreases 3 MED-
induced thymine dimer formation. Biopsies from eight subjects with a low
MED who had been exposed to 3MED of that individual on day 0 and again
on day 90 upon completion of the study were used for assessment of thymine
dimers. Sections were stained by immunohistochemistry and thymine dimers
were quantitated by counting thymine dimer-positive nuclei throughout the
whole thickness of the epidermis, or only in the basal layer of the epidermis
and expressed as positively stained cells per mm length. The meanþ SEM is
shown for each group. Statistical comparisons (paired t-test) were performed
between samples taken at baseline on day 0 and at day 90 upon completion
of the study in the same subjects.
a b
Figure 9. Photomicrographs of sections of epidermis labelled to visualize
thymine dimers. Representative photomicrographs of one subject with a low
MED who had been exposed to 3 the subject’s MED on (a) day 0 (83% cells
positive) and (b) again on day 90 upon completion of the study (14% cells
positive). Thymine dimers are identified as brown staining in the nuclei of
cells of the epidermis. Reduction of staining is evident in (b), particularly in
the basal layer. Bar¼ 0.10 mm.
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melanin. Therefore, a change from 1 to 3% in the skin
content of melanin or an approximately three-fold increase
may provide significant added protection against sun-
induced skin cancer.
One of several possible mechanisms of UV-induced
tanning is that sunlight damages the skin cells and triggers
both keratinocytes and melanocytes to produce a-MSH
(Gilchrest et al., 1996). Tanning then occurs in response to
the damage and the skin now has increased protection from
sunlight. In nature, this protection has come too late to
prevent the skin damage (sunburn or skin cancer) that
occurred before the instigation of tanning. [Nle4-D-Phe7]-a-
MSH stimulates the skin to produce the protective tan before
the sunlight can damage the skin.
The effect of systemic a-MSH administration on human
(Negroid) pigmentation was first published by Lerner and
McGuire (1961) more than 40 years ago. More recently,
studies (Dorr et al., 2000, 2004; Levine et al., 1991, 1999)
using the synthetic analogue of a-MSH, [Nle4-D-Phe7]-a-
MSH, administered over 10 days have demonstrated in-
creased tanning of the skin, but this has been generally
confined to sun-exposed areas of the skin and to predomi-
nantly people of skin type III/IV. Interestingly, in this study,
the major side effects of [Nle4-D-Phe7]-a-MSH were similar to
those previously reported (Levine et al., 1991, 1999; Dorr
et al., 2000, 2004). Interestingly, there were no reports of
spontaneous erections, which indicates that the linear
analogue of a-MSH, at least at the dosage used in this study,
has a different pharmacodynamic profile to the cyclic
peptide, which is currently being tested for the treatment of
erectile dysfunction. Adverse events in the third month of
treatment were similar and slightly less predominant than in
the first month. This is the first study in which [Nle4-D-Phe7]-
a-MSH has been given over such a prolonged period of time
and the fact that this did not produce cumulative, more
intense or new side effects attests to the relatively good safety
record for this drug.
It is possible that the high incidence of nausea, vomiting,
and peripheral vasodilation, which mainly occurred in the
immediate post-dose period, may have been the result of the
rapid rate of absorption from the administration site and the
consequently relatively high but short-lived (half-life is
30 minutes) blood level. The incidences of these adverse
events could potentially be reduced by reformulation of the
drug as a sustained release injection that will result in a
markedly lower plasma concentration.
It is anticipated that this will attenuate most side effects
associated with the first few hours of bolus injection.
In previous studies, the increased darkening of the skin has
been reported using the L* and b* indices of chromaticity
matching the Commission Internationale de l’Eclairage
standard observer response (Westerhof et al., 1986; Weath-
erall and Coombs, 1992; Alaluf et al., 2002). We used both
chromaticity and a new method to monitor skin darkening.
The reduction of 1–2 on the L* chromaticity scale in this study
is similar but slightly lower than previous reports of skin
tanning using [Nle4-D-Phe7]-a-MSH at this dosage (Levine
et al., 1991; Dorr et al., 2004). In this study, participants were
encouraged to avoid the sun where possible and to use
sunblock when exposed, and this may account for the
relatively small change in luminance units. It is noteworthy
that Dorr et al. (2004) obtained a mean 10-unit decrease in
luminance when [Nle4-D-Phe7]-a-MSH administration was
combined with sunlight exposure. Our results indicate that
the estimation of MD by the method of Dwyer et al. (1998)
appears to provide a good estimation of melanin changes as
shown by the actual biopsy measurements. The actual
increase in histological measurement of melanin in the
biopsies of the lower back showed changes that correlated
extremely well with the MD spectrophotometric assessment
at a similar, non-sun-exposed skin site. That is, melanin
increased by 60 and 0%, respectively, in the low-MED skin
type and the high-MED skin types when measured micro-
scopically at the lower back and by 60 and 11% when
assessed non-invasively by spectrophotometry at the lower
abdomen. Although there was no direct comparison at the
same anatomical site, the results are very supportive that MD
measurement is an accurate reflection of the actual tissue
melanin content. We believe that this MD measurement
should be used in future studies to measure changes in
human skin pigmentation. The advantages over the chroma-
ticity values are that the results appear more consistent and
also give an actual representation of the melanin change
rather than an indirect hue or luminicity value.
[Nle4-D-Phe7]-a-MSH had the greatest impact on those
people with the lowest constitutive melanin and therefore the
greatest risk of sunburn injury. In some people with the
lowest baseline skin melanin, a doubling of their constitutive
melanin was achieved. Importantly, the increase in MD
appeared to be just as pronounced in non-sun-exposed skin
sites (abdomen, inner upper arm) as in sun-exposed sites
(forehead and neck). The increased melanin in the skin was
maintained for at least 3 weeks after the drug regime had
finished. Previous studies of just 10 days of a similar drug
dosage regimen have shown maintained skin darkening for
up to 3 or 4 weeks after the end of treatment (Levine et al.,
1991, 1999). Extended duration of melanization after the end
of treatment is very likely because of the residence time that
melanin will remain in the keratinocytes until the normal
process of desquamation removes them; there may also be an
extended duration of increased melanin production within
the melanocytes. Also in a recent paper (Dorr et al., 2004), it
was shown that [Nle4-D-Phe7]-a-MSH in combination with a
minimal amount of sun exposure extended the skin tanning
effect from about 4 weeks with [Nle4-D-Phe7]-a-MSH alone to
at least 11 weeks with 30-minute sun exposure a day for 3–5
days.
Of particular interest is the increase seen in the inner
upper arm (increase of 0.8570.09 with [Nle4-D-Phe7]-a-MSH
vs decrease of 0.370.11 in placebo), as this is the area
designated as being most representative of constitutive mela-
nin at birth and the least likely affected by environmental
factors (Dwyer et al., 2002).
The decrease in average skin melanin levels in the placebo
group at all skin sites measured was an unexpected result but
was most probably due to seasonal variation (van der Mei
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et al., 2002). The study was conducted from mid-summer
through Autumn to early winter and suggests that skin
melanin built up over summer may decline by about
6–12% during the winter months, at least in people residing
in the relative sunny climes of southern Australia. At the two
investigative sites (Sydney and Adelaide), the monthly UV
index at the start of the study in January (extreme high) was
approximately five-fold greater than at the end of the study in
July (low) (Australian Government Bureau of Meteorology,
1997–2001). More dramatic changes could be expected in
countries with relatively sunny summers and long sunless
winters.
The estimation of skin cell damage using 3MED of UVR
exposure is well accepted (Dorr et al., 2004). Although two
different solar simulators were used in this study, the MED
estimations at both study centers were remarkably consistent
with no statistical difference between the two sites. Therefore,
values could be combined in our analysis. Our results would
tend to support the concept that increased melanin levels can
attenuate UV damage. However, the variable effect in the
placebo group resulted in an unexpected although not
significant reduction in sunburn cells. This result cannot be
explained, except to state that there may be a wide variation
in the response to 3MED in different people and larger
numbers may be needed to adequately determine this effect.
It also provides a cautionary note when extrapolating
increased melanin levels to photoprotection. Increased
melanin levels per se may not necessarily be associated with
increased photoprotection. Epidemiological data would
suggest that an increase of two- or three-fold in the
constitutive melanin level may be needed to afford protection
(Dwyer et al., 2002). This would depend on the constitutive
melanin level, for example, those individuals with a low MED
threshold who have constitutive melanin levels around 1–2 in
our study would need to increase to 3 or more to provide
significant extra defense against UV skin damage. When
coupled with adequate sunscreen use and sensible exposure
times, this could lead to greater freedom for outdoor activities
to a vast number of individuals who are currently limited to
indoor lifestyles. Further studies are planned to explore this
important potential.
Results of our thymine dimer assessment indicated that the
[Nle4-D-Phe7]-a-MSH-treated group showed a real reduction
in DNA damage. This is important for the interpretation of the
reduction in apoptotic (sunburn) cells in our study, which
could otherwise be interpreted as a reduction in the skin’s
protective mechanism to induce cell death on UV-induced
DNA-damaged cells. However, it must be noted that because
these studies were performed 24 hours after UV exposure, the
burden of DNA photoproducts reflects both the rate of repair
and the extent of initial protection. Consequently, sunburn
cells and photoproducts were assessed at the same time. It
also demonstrated that a protective effect is seen in the
epithelial basal layer, which may contain the long-lived stem
cells and it is these cells in which the damage may persist and
increase the risk of cancer (Morris, 2000). The basal layer is
damaged mainly by UVA radiation and this finding is
important in reference to a recently published paper
indicating that UVA may play a far greater role in human
skin carcinogenesis than was previously realized (Agar et al.,
2004).
This study has, for the first time, indicated the potential to
provide photoprotection to melanocompromised Caucasians
by converting them into melanocompetent persons (Fitzpatrick
and Bolognia, 1995). In the face of increased deterioration of
the ozone layer, especially in Australia (Ewan et al., 1991),
and the increasing incidence of skin cancer (Armstrong and
Kricker, 1994), the ability to stimulate the skin’s own
‘‘protective mechanism’’ of tanning may prove extremely
important as an additional photoprotective strategy.
MATERIALS AND METHODS
Study design
This was a double-blinded, randomized, placebo-controlled study
conducted in accordance with the Declaration of Helsinki Principles
and ICH guidelines for Good Clinical Practice including written
informed consent from all subjects. Ethical approval to conduct the
study was obtained from the Central Sydney Area and the Royal
Adelaide Hospital Human Ethics Committees. The population
consisted of male and female Caucasian subjects accrued in a 3:1
[Nle4-D-Phe7]-a-MSH to placebo ratio. [Nle4-D-Phe7]-a-MSH was
prepared by solid-phase chemistry under GMP conditions at
Bachem, Peninsula Laboratories (San Carlos, CA). Single-use sterile
6 ml vials each containing 16 mg of [Nle4-D-Phe7]-a-MSH in 1 ml
sterile saline for injection and placebo vials were prepared under
GMP conditions by Octoplus (Leiden, The Netherlands).
Before treatment, each volunteer’s baseline skin pigmentation
was measured and the volunteers’ MED response determined on the
lower back. A small area on the back was then exposed to 3 each
individual’s MED and punch biopsies collected from the exposed
and an adjacent unexposed area 24 hours later for histological
evaluation. Subjects were assigned to a low- or high-MED subgroup.
This was based on a prospectively assigned cutoff level. Sensitive
skin types (easily burning) were defined as having an MEDo450 mJ/
cm2, thus the low-MED group defined a group of subjects with a
sensitive skin type akin to Fitzpatrick I/II. Assignment to photo-
sensitivity as defined by UV exposure was preferred to a subjective
questionnaire of Fitzpatrick skin type as the latter was found to be
inconsistent with actual photosensitivity.
Treatments (0.16 mg/kg/day or placebo) were injected subcuta-
neously in the abdomen each day for 5 consecutive days a week  2
weeks. Each subject’s body weight was determined at check-in and
the same weight used for all dose calculations for the first 10 days of
treatment. This cycle of treatment was repeated at days 29–40 and
57–68 resulting in a total of 30 daily bolus injections over the
complete study period. Each subject was reweighed at the start of
each dosing period for calculation of dose. Skin reflectance
measurements were taken throughout the study period and blood
samples were periodically taken to monitor safety and vital signs
recorded at every visit. The study was performed in late autumn and
winter; all subjects were adviced to apply sun protection factor 25þ
sunscreen to exposed skin and to cover up whenever they expected
to be in the sun for prolonged periods of time (430 minutes).
After 90 days, volunteers were exposed to 3 their individual
MED (assessed at the beginning of the study) and a further two
biopsies taken.
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Assessment of pigmentation by skin reflectance measurements
Before treatment (baseline) and at days 12, 30, 40, 60, and 90,
subjects had their skin pigmentation measured by a non-invasive
quantitative skin chromaticity (reflectance) readings. Reflectance by
the skin of wavebands of light measured at 20-nm intervals in the
wavelength range 400–700 nm was recorded using a Minolta
spectrophotometer (Minolta, Osaka, Japan). Eight different anatomi-
cal sites were assessed (forehead, cheeks, neck, scapula, inner upper
arm, forearm, abdomen, and calf). The average of three separate
measurements at each site was determined. Measurement positions
for all eight skin sites at baseline were recorded on an outline
body chart to ensure that subsequent measurements were always
taken at exactly the same skin site. Two measures of reflectance
were recorded: (1) luminance (L*), one of the three indices of
chromaticity designated L*a*b* matching the Commission Inter-
nationale de l’Eclairage standard observer response (Weatherall and
Coombs, 1992), and (2) reflectance by the skin of wavebands of light
centered at 400 and 420 nm. Using the measurement of reflectance
at 420 nm minus that at 400 nm, a reasonable prediction of the
melanin content of the skin is obtained, as described by Dwyer et al.
(1998). The cutaneous melanin estimated from skin reflectance is
reported as ‘‘MD’’ and is equivalent to the epidermal melanin
intensity as routinely determined by optical density measurement
of light microscopy sections stained for melanin granules. For
Caucasians, this generally ranges from 1 to 5 density units (Dwyer
et al., 2002).
Determination of minimal erythema dose
At one site (Royal Adelaide Hospital (CMAX), Adelaide), a model
16S Solar UV Simulator (Solar Light Co., Philadelphia, PA) with a
150 W xenon lamp filtered by a dichroic mirror and a 1 mm WG320
filter (Schott Corporation, Elmsford, NY) was used to produce a
spectrum that closely matched the UV portion of sunlight
(290–400 nm). Irradiance and spectra were monitored with a
spectroradiometer containing a 1680 B double monochromator
(SPEX industries, Edison, NJ). Daily UV doses were determined using
a PMA2100 broadband radiometer equipped with a PMA2105 UVB
detector (Solar Light Co.) calibrated against the solar simulator with
the monochrometer.
At the other site (Royal Prince Alfred Hospital, Sydney), a
1,000 W xenon arc solar simulator (Oriel, Stratford, CT) filtered by
two 280–400 nm dichroic mirrors and an atmospheric attenuation
filter (Oriel catalogue number 81017) was used to produce a
spectrum closely matching the UV portion of sunlight. Irradiance
and spectra were monitored with a scanning spectrophotometer
(Optronics, Orlando) and UV output monitored daily with an IL1350
broadband radiometer using SED 038 (UVA) and SED 240 (UVB)
detectors (International Light, Newburyport) that were calibrated
against the source with the spectrophotometer.
Each subject’s MED was determined by exposing 10 sites in a
grid pattern on the lower back/buttock to varying levels of UV.
The MED was determined as the lowest UV dose that resulted in
just perceptible erythema with clearly defined borders 24 hours
later.
Exposure to 3MED UVR for biopsy
Exposure of 3 each individual’s baseline MED to the lower
back/buttock area (contra-lateral to the initial MED exposure) was
performed before the initial drug administration and repeated at day
90, approximately 24 days after completion of drug administration.
Each subject had one 10 mm circle of skin exposed to solar-
simulated UVR. The area next to this site was covered with a
screening patch during the administration of UV light to prevent
indirect UV light exposure during this procedure affecting this
adjacent skin area.
A 3 mm punch biopsy was collected from the exposed and
adjacent shielded skin approximately 24 hours after UVR exposure
for sunburn cell quantitation (apoptotic cells and thymine dimer
counts) and microscopic evaluation of MD. Each biopsy was
immediately fixed in 10% phosphate-buffered formalin for routine
processing, paraffin embedding, and sectioning.
Quantification of apoptotic (sunburn) cells, thymine dimers,
and tissue melanin
Quantification of sunburn or apoptotic cells was determined
using published histopathologic end points (Gilchrest et al.,
1981; Schwarz et al., 1997). Sections (5mm) from all subjects
assigned to the low-MED group were dewaxed, rehydrated,
and stained with hematoxylin and eosin. Sunburn cells were
identified by light microscopy within the epidermis as having a
shrunken eosinophilic cytoplasm and a condensed nucleus. All
epidermal sunburn cells within the entire specimen were counted
with the aid of a grid and were expressed as per mm length of
epidermis. Sections were also stained with Masson-Fontana
stain and the number of melanin-containing cells quantitated
by image analysis of light microscopy sections using a Zeiss KS-
400 image analysis system. All measurements of sunburn cells and
melanin levels were performed by an independent pathologist
working ‘‘blind’’.
Additionally, sections from eight [Nle4-D-Phe7]-a-MSH-treated
subjects from the low-MED group were examined for thymine dimer
production before and after treatment. These sections were micro-
waved in citrate buffer to facilitate antigen retrieval followed by
incubation in 0.07 N sodium hydroxide for 4 minutes and blocking in
10% goat serum for 30 minutes. One section was then labelled for
thymine dimers by incubation with the TDM-1 antibody (1/1,000;
Kamiya Biomedical, Gateway Drive, Seattle, WA) and the other
was used as a negative control. Slides were incubated at room
temperature for 1 hour, washed in phosphate-buffered saline, and
incubated with biotinylated secondary antibody (Vector goat
anti-mouse IgG, 1/400) for 45 minutes. Staining was detected using
chromagen 3-30-diaminobenzidine followed by counterstaining with
thionine to reveal the nuclei. TDM-1-positive cells were counted
at  20 magnification for the full thickness of the epidermis and
expressed as positive cells/mm epidermal length. Negative controls
were used to validate the method.
Statistical analysis
The statistical analysis was carried out using SAS (version 8.2)
statistical software from SAS Institute Inc. (Cary, NC). Data were
analyzed using analysis of variance techniques. The analysis of
variance model included terms for treatment and skin types and their
two-way interaction. All statistical tests of significance were
performed at the 5% level of significance and were two-sided
unless otherwise stated. In all comparisons within the same group of
subjects, a paired t-test was used.
1876 Journal of Investigative Dermatology (2006), Volume 126
RStC Barnetson et al.
UVR Protection by Increased Skin Melanin
CONFLICT OF INTEREST
Ross Barnetson is a member of the Medical Advisory Panel to Clinuvel
Pharmaceuticals Limited; Stuart Humphrey previously worked for and
Michael Kleinig is a current employee of Clinuvel Pharmaceuticals Limited,
Melbourne, Australia.
ACKNOWLEDGMENTS
We are grateful to CMAX (division of IDT Australia Ltd) for able clinical
assistance at the Royal Adelaide Hospital. This study was carried out at the
Royal Prince Alfred Hospital, Sydney, Australia and Royal Adelaide Hospital,
Adelaide, Australia.
REFERENCES
Abdel-Malek Z, Scott MC, Suzuki I, Tada A, Im S, Lamoreux L et al. (2000)
The melanocortin-1 receptor is a key regulator of human cutaneous
pigmentation. Pigment Cell Res 13(Suppl 8):156–62
Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C (1999) The melanocortin-1
receptor and human pigmentation. Ann NY Acad Sci 885:117–33
Agar NS, Halliday GM, Barnetson RS, Ananthaswamy HN, Wheeler M, Jones
AM (2004) The basal layer in human squamous tumors harbors more
UVA than UVB fingerprint mutations: a role for UVA in human skin
carcinogenesis. Proc Natl Acad Sci USA 101:4954–9
Alaluf S, Atkins D, Barrett K, Blount M, Carter N, Heath A (2002) Ethnic
variation in melanin content and composition in photoexposed and
photoprotected human skin. Pigment Cell Res 15:112–8
Armstrong BK, Kricker A (1993) How much melanoma is caused by sun
exposure? Melanoma Res 3:395–401
Armstrong BK, Kricker A (1994) Cutaneous melanoma. Cancer Survey 19/
20:219–40
Australian Government Bureau of Meteorology (1997–2001) Monthly average
UV index. www.bom.gov.au
Box NF, Duffy DL, Irving RE, Russell A, Chen W, Griffyths LR et al. (2001)
Melanocortin-1 receptor genotype is a risk factor for basal and squamous
cell carcinoma. J Invest Dermatol 116:224–9
Castrucci AM, Hadley M.E, Sawyer TK, Hruby VJ (1984) Enzymological
studies of melanotropins. Comp Biochem Physiol B 78:519–24
Chaturvedi DN, Hadley ME (1988) Melanotropic peptides: biomedical
applications. In: The melanotropic peptides (Hadley ME, ed), Vol III.
Boca Raton, FL: CRC Press, 129–50
Chedekel MR (1995) Photophysics & photochemistry of melanin. In: Melanin:
its role in human photoprotection (Zeise L, Chedekel MR, Fitzpatrick TB,
eds), Overland Park, KS: Valdenmar Publishing Co., 11–22
Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K et al. (2000)
Increased eumelanin expression and tanning is induced by a superpotent
melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photo-
biol 72:526–32
Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB et al. (2004)
Effects of a superpotent melanotropic peptide in combination with solar
or ultraviolet radiation on tanning of the skin in human volunteers. Arch
Dermatol 140:827–35
Dwyer T, Blizzard L, Ashbolt R, Plumb J, Berwick M, Stankovich JM (2002)
Cutaneous melanin density of Caucasians measured by spectrophoto-
metry and risk of malignant melanoma, basal cell carcinoma, and
squamous cell carcinoma of the skin. Am J Epidemiol 155:614–21
Dwyer T, Muller HK, Blizzard L, Ashbolt R, Phillips G (1998) The use of
spectrophotometry to estimate melanin density in Caucasians. Cancer
Epidemiol Biomarkers Prev 7:203–6
Dwyer T, Prota G, Blizzard L, Ashbolt R, Vincensi MR (2000) Melanin density
and melanin type predict melanocytic naevi in 19–20 year olds of
northern European ancestry. Melanoma Res 10:1–8
Epstein JH (1983) Photocarcinogenesis, skin cancer and aging. J Am Acad
Dermatol 9:487–502
Ewan C, Bryant EA, Calvert GD, Marthick J, Condon-Paoloni D (1991)
Potential health effects of greenhouse effect and ozone layer depletion in
Australia. Med J Aust 154:554–9
Fitzpatrick TB (1988) The validity and practicality of sun-reactive skin types I
through VI. Arch Dermatol 124:869–71
Fitzpatrick TB, Bolognia JL (1995) Human melanin pigmentation: role in
pathogenesis of cutaneous melanoma. In: Melanin: its role in human
photoprotection. (Zeise L, Chedekel MR, Fitzpatrick TB, eds), Overland
Park, KS: Valdenmar Publishing Co., 177–82
Furumura M, Sakai C, Abdel-Malek Z, Barsh G, Hearing VJ (1996)
The interaction of agouti signal protein and melanocyte stimulation
hormone to regulate melanin formation in mammals. Pigment Cell Res 9:
191–203
Gilchrest BA, Park HY, Eller MS, Yaar M (1996) Mechanisms of ultraviolet
light-induced pigmentation. Photochem Photobiol 63:1–10
Gilchrest BA, Soter NA, Stoff JS, Mihm MC Jr (1981) The human sunburn
reaction: histologic and biochemical studies. J Am Acad Dermatol
5:411–22
Hadley ME, Sharma SD, Hruby VJ, Levine N, Dorr RT (1993) Melanotropic
peptides for therapeutic and cosmetic tanning of the skin. Ann NY Acad
Sci 680:424–39
Hruby VJ, Sharma JD, Toth K, Jaw JY, al Obeidi F, Sawyer TK et al. (1993)
Design, synthesis, and conformation of superpotent and prolonged
acting melanotropins. Ann NY Acad Sci 680:51–63
Hunt G, Kyne S, Ito S, Wakamatsu K, Todd C, Thody A (1995a) Eumelanin
and phaeomelanin content of human epidermis and cultured melano-
cytes. Pigment Cell Res 8:202–8
Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ (1995b) Nle4DPhe7
alpha-melanocyte-stimulating hormone increases the eumelanin:phaeo-
melanin ratio in cultured human melanocytes. J Invest Dermatol
104:83–5
Kaidbey KH, Agin PP, Sayre RM, Kligman AM (1979) Photoprotection by
melanin – a comparison of black and Caucasian skin. J Am Acad
Dermatol 1:249–60
Kollias N, Malallah YH, al Ajmi H, Bager A, Johnson BE, Gonzalez S (1996)
Erythema and melanogenesis action spectra in heavily pigmented
individuals as compared to fair-skinned Caucasians. Photodermatol
Photoimmunol Photomed 12:183–8
Kollias N, Sayre RM, Zeise L, Chedekel MR (1991) Photoprotection by
melanin. J Photochem Photobiol B 9:135–60
Kricker A, Armstrong BK, English DR, Heenan PJ (1995a) A dose–response
curve for sun exposure and basal cell carcinoma. Int J Cancer 60:482–8
Kricker A, Armstrong BK, English DR, Heenan PJ (1995b) Does intermittent
sun exposure cause basal cell carcinoma? A case–control study in
Western Australia. Int J Cancer 60:489–94
Lerner AB, McGuire JS (1961) Effect of alpha- and beta-melanocyte
stimulating hormones on the skin colour of man. Nature 189:
176–9
Levine N, Dorr RT, Ertl GA, Brooks C, Alberts DS (1999) Effects of a potent
synthetic melanotropin, Nle4-D-Phe7alpha-MSH (Melanotan) on tanning:
dose ranging study. J Dermatol Treat 10:127–32
Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC et al. (1991)
Induction of skin tanning by subcutaneous administration of a potent
synthetic melanotropin. JAMA 266:2730–6
Morris R (2000) Keratinocyte stem cells: targets for cutaneous carcinogens.
J Clin Invest 106:3–8
Palmer JS, Duffy DL, Box NF, Aitken JF, O’Gormon LE, Green AC et al. (2000)
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the
association explained solely by pigmentation phenotype? Am J Hum
Genet 66:176–86
Pathak MA (1995) Functions of melanin and protection by melanin. In:
Melanin: its role in human photoprotection. (Zeise L, Chedekel MR,
Fitzpatrick TB, eds), Overland Park, KS: Valdenmar Publishing Co., 125–34
Prota G (1980) Recent advances in the chemistry of melanogenesis in
mammals. J Invest Dermatol 75:122–7
Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB et al.
(1980) 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating
hormone: a highly potent alpha-melanotropin with ultralong biological
activity. Proc Natl Acad Sci USA 77:5754–8
www.jidonline.org 1877
RStC Barnetson et al.
UVR Protection by Increased Skin Melanin
Schwarz A, Mahnke K, Luger TA, Schwarz T (1997) Pentoxifylline reduces the
formation of sunburn cells. Exp Dermatol 6:1–5
Sober AJ, Lew RA, Koh HK, Barnhill RL (1991) Epidemiology of cutaneous
melanoma. An update. Dermatol Clin 9:617–29
Stenback F (1978) Life history and histopathology of ultraviolet
light-induced skin tumors. Natl Cancer Inst Monogr 50:
57–70
Thody AJ (1999) alpha-MSH and the regulation of melanocyte function. Ann
NY Acad Sci 885:217–29
Thody AJ, Higgins EM, Wakamatsu K, Ito S, Burchill SA, Marks JM (1991)
Pheomelanin as well as eumelanin is present in human epidermis.
J Invest Dermatol 97:340–4
Valverde P, Healy E, Jackson I, Rees JL, Thody AJ (1995) Variants of the
melanocyte-stimulating hormone receptor gene are associated with red
hair and fair skin in humans. Nat Genet 11:328–30
van der Mei I, Blizzard L, Stankovich J, Ponsonby AL, Dwyer T (2002)
Misclassification due to body hair and seasonal variation on melanin
density estimates for skin type using spectrophotometry. J Photochem
Photobiol B 68:45–52
Weatherall IL, Coombs BD (1992) Skin color measurements in terms of
CIELAB color space values. J Invest Dermatol 99:468–73
Westerhof W, van Hasselt BA, Kammeijer A (1986) Quantification of UV-
induced erythema with a portable computer controlled chromameter.
Photodermatology 3:310–4
1878 Journal of Investigative Dermatology (2006), Volume 126
RStC Barnetson et al.
UVR Protection by Increased Skin Melanin
